Swati Wadhawan, Vishal Kumar Biswkarma, A. Chaudhary, Priya Masand
{"title":"A Critical Review Based on Preclinical Studies of Medicinal Plants for the\nManagement of Alzheimer’s Disease","authors":"Swati Wadhawan, Vishal Kumar Biswkarma, A. Chaudhary, Priya Masand","doi":"10.2174/1573407219666230807150426","DOIUrl":null,"url":null,"abstract":"\n\nAlzheimer’s disease (AD) is the most common neurodegenerative and progressive disorder that results in damage to memory and alters thinking and behavior, which represent critical\nproblems the world’s aging population is faced with. Clinical symptoms of AD include cognitive\ndecline, loss of memory, emotional and behavioral changes, loss of motor coordination, and mental\nimpairments. Yet, neither a universally accepted diagnosis with respect to its pathogenesis nor an\nideal therapy is available for the management of AD. The existing drugs cause many complications\nand adverse effects. Herbal drugs, supported by an abundance of traditional knowledge, may fulfill\nthe need as they can target the pathogenesis of AD at various destinations, both at the cellular and\nmolecular levels. In recent years, herbal drugs and formulations have been evaluated in preclinical\nsetups, especially involving rat and mouse models of AD, which have shown their memoryenhancing, neuroprotective, and antioxidant activities. Several herbal drugs and phytochemicals\nhave been evaluated for their effectiveness as antioxidative agents to prevent the occurrence of oxidative stress and ROS formation during AD pathogenesis and exhibit antiapoptotic properties by\ndownregulating caspase-3, DNA fragmentation, NF-κB, interleukin-1 β (IL1β), and TNF levels. In\nthis paper, we have primarily reviewed herbal remedies that have been recently evaluated as alternative treatments for AD in a preclinical setup, and discussed the role of herbal medicines in the\nmanagement of AD and advances in their knowledge.\n","PeriodicalId":10772,"journal":{"name":"Current Bioactive Compounds","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Bioactive Compounds","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573407219666230807150426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative and progressive disorder that results in damage to memory and alters thinking and behavior, which represent critical
problems the world’s aging population is faced with. Clinical symptoms of AD include cognitive
decline, loss of memory, emotional and behavioral changes, loss of motor coordination, and mental
impairments. Yet, neither a universally accepted diagnosis with respect to its pathogenesis nor an
ideal therapy is available for the management of AD. The existing drugs cause many complications
and adverse effects. Herbal drugs, supported by an abundance of traditional knowledge, may fulfill
the need as they can target the pathogenesis of AD at various destinations, both at the cellular and
molecular levels. In recent years, herbal drugs and formulations have been evaluated in preclinical
setups, especially involving rat and mouse models of AD, which have shown their memoryenhancing, neuroprotective, and antioxidant activities. Several herbal drugs and phytochemicals
have been evaluated for their effectiveness as antioxidative agents to prevent the occurrence of oxidative stress and ROS formation during AD pathogenesis and exhibit antiapoptotic properties by
downregulating caspase-3, DNA fragmentation, NF-κB, interleukin-1 β (IL1β), and TNF levels. In
this paper, we have primarily reviewed herbal remedies that have been recently evaluated as alternative treatments for AD in a preclinical setup, and discussed the role of herbal medicines in the
management of AD and advances in their knowledge.
阿尔茨海默病(AD)是一种最常见的神经退行性和进行性疾病,它会导致记忆损伤,改变思维和行为,这是世界人口老龄化面临的关键问题。阿尔茨海默病的临床症状包括认知能力下降、记忆丧失、情绪和行为改变、运动协调能力丧失和精神障碍。然而,对于阿尔茨海默病的发病机制,既没有普遍接受的诊断,也没有理想的治疗方法。现有的药物引起许多并发症和不良反应。在丰富的传统知识的支持下,草药可能会满足这一需求,因为它们可以在细胞和分子水平上针对阿尔茨海默病的发病机制。近年来,草药及其制剂已在临床前研究中进行了评估,特别是在大鼠和小鼠AD模型中,显示出其增强记忆、神经保护和抗氧化活性。一些草药和植物化学物质已被评估其作为抗氧化剂的有效性,以防止AD发病过程中氧化应激的发生和ROS的形成,并通过下调caspase-3、DNA片段化、NF-κB、白细胞介素-1 β (il -1 β)和TNF水平表现出抗凋亡特性。在本文中,我们主要回顾了最近被评估为阿尔茨海默病临床前替代治疗方法的草药,并讨论了草药在阿尔茨海默病管理中的作用及其知识进展。
Current Bioactive CompoundsPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.90
自引率
0.00%
发文量
112
期刊介绍:
The journal aims to provide comprehensive review articles on new bioactive compounds with proven activities in various biological screenings and pharmacological models with a special emphasis on stereoeselective synthesis. The aim is to provide a valuable information source of bioactive compounds synthesized or isolated, which can be used for further development of pharmaceuticals by industry and academia. The journal should prove to be essential reading for pharmacologists, natural product chemists and medicinal chemists who wish to be kept informed and up-to-date with the most important developments on new bioactive compounds of natural or synthetic origin, including their stereoeselective synthesis.